Centers for Disease Control and Prevention

National Center for Immunization and Respiratory DiseasesPhotographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation 

use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Epidemiology of Respiratory Syncytial Virus Hospitalizations in Adults — RSV-NETAdvisory Committee on Immunization Practices, October 25, Monica E. Patton, MDDeputy Lead, RSV-NETSurveillance and Prevention BranchCoronavirus and Other Respiratory Viruses Division
 RESP-NET: RSV-NET, COVID-NET, FluSurv-NET Active, population-based surveillance of 

laboratory-confirmed RSV-associated hospitalizations – >300 acute-care hospitals, 58 counties in 12 states – ~8.6% of U.S. population

 Tests positive for RSV within 14 days prior to 

or during hospitalization – Clinician-driven testing

 Clinical data: random sample of RSV-NET 

patients stratified by age and site

RSV-NET: A RESP-NET population-based hospitalizsurveillance platform

California

Oregon

Utah

Colorado

NewMexico

Minnesota 

RSV-NET with pepopulatparticipcounties
Age groups presented today for adults aged ≥18 Age Group Background/Rationale18–49 years Youngest adult group50–59 years Age group for which we are reviewing data today60–64 years 60 is youngest age currently recommended for RSV vaccination, with shar

decision making, in the U.S.

65–74 years

65 is a common definition of “older adults” and used for other vaccine re• Certain influenza vaccine formulations• Universal pneumococcal vaccination• Age of most Medicare eligibility

≥75 years 75 is the age at which RSV vaccination was recommended by the United K

Committee on Vaccination and Immunisation (JCVI)*

*https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisatioand-older-adults-jcvi-full-statement-11-september-2023
Epidemiology of RSV–associated hospitaliz

among adults aged 50–59 years

• Demographics• Rates of RSV-associated hospitalizations• Underlying medical conditions• Severe outcomes (ICU admission, mechanical ventilation, death)

• Comparison of RSV v. influenza v. COVID-19

• Will not present rates of RSV-associated hospitalizations stratified 

conditions
Characteristic Unweighted N=17,847 Weighted %Age (years)

18–49 years 2,435 13.6

50–59 years 2,492 14.060–64 years 1,790 10.065–74 years 4,079 22.9≥75 years 7,051 39.5

Race and ethnicity*

White 10,755 62.2Black 3,529 20.4Hispanic 1,434 8.3Asian or Pacific Islander 1,020 5.9American Indian or Alaska Native 90 0.5Multirace 89 0.5Unknown 367 2.1

Characteristics of non-pregnant adults ≥18 years hwith lab-confirmed RSV, RSV-NET, 2014–2015 to 20

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o

  
Adjusted RSV-associated hospitalization rates* per 100,000 adby 5-year age group and year, RSV-NET, 2015–2016 to 2019–2*Unpublished data. Rates are adjusted for the frequency of RSV testing during each season and the sensitivity of RSV diagnostic tests.

0

100200300400500600

18–49 50–54 55–59 60–64 65–69 70–74 75–79 

Annual RSV-associated hospitalizations per 

100,000 population 

2015–16 2016–17 2017–18 2018–19 2019–20

26–59

23–42
0

50

100150200250

Oct-22

Nov-22

Dec-22

Jan-23

Feb-23

M23

Rate per 100,000 population

Unadjusted monthly and cumulative RSV-associated rates* among adults ≥18 years — RSV-NET, 2022–202

0

10203040506070

May-22

Jun-22

Jul-22

Aug-22

Sep-22

Oct-22

Nov-22

Dec-22

Jan-23

Feb-23

Mar-23

Apr-23

May-23

Jun-23

Jul-23

Aug-23

Sep-23

Rate per 100,000 population

18-49 years 50-59 years 60-64 years 65-74 years 75+ years

Cumul

October 2022

Monthly rates 

May 2022–September 2023

*Rates have not been adjusted for RSV testing practices and underestimate actual rates of RSV-associated hospitalizations, as not all people hospitalized with respiratory illness 

testing practices may differ by disease severity, age, and/or racial and ethnic group of patients and may have changed over time.
Underlying medical conditions* among non-pregnant adults ≥18 years associated hospitalizations — RSV-NET, 2014–2015 to 2017–2018 and 2

Major underlying condition categories Unweighted 

N=7,479

Weighted 

%

Cardovascular disease (overall) 5,141 57.4Obesity 2,798 39.0Diabetes 2,484 34.1COPD 2,248 31.4Heart failure 1,984 28.0Chronic kidney disease 2,003 27.0Asthma 1,789 24.0Coronary artery disease (includes CABG, MI) 1,718 24.

0

Neurologic condition 1,628 22.6Immune compromised 1,567 20.8Chronic metabolic disease, not including diabetes 1,417 19.3Other chronic lung disease 995 17.1Chronic liver disease 538 7.2Autoimmune/inflammatory disease 310 4.5Blood disorders 287 4.1

94.3% years associhospitleast omedic• 31.4• 62.9

*Clinical data, including underlying medical conditions, were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations during the 2022–2023 season. Data are presented as unweigpercentages that were weighted for the probability of selection.
Underlying medical conditions* among non-pregnant adults ≥18 years associated hospitalizations — RSV-NET, 2014–2015 to 2017–2018 and 2

Major underlying condition categories Unweighted 

N=7,479

Weighted 

%

Cardovascular disease (overall) 5,141 57.4Obesity 2,798 39.0Diabetes 2,484 34.1COPD 2,248 31.4Heart failure 1,984 28.0

Chronic kidney disease 2,003 27.0Asthma 1,789 24.0Coronary artery disease (includes CABG, MI) 1,718 24.

0

Neurologic condition 1,628 22.6Immune compromised 1,567 20.8Chronic metabolic disease, not including diabetes 1,417 19.3Other chronic lung disease 995 17.1Chronic liver disease 538 7.2Autoimmune/inflammatory disease 310 4.5Blood disorders 287 4.1

94.3% years associhospitleast omedic• 31.4• 62.9

*Clinical data, including underlying medical conditions, were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations during the 2022–2023 season. Data are presented as unweigpercentages that were weighted for the probability of selection.
0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-co

2022–2023 season. Displayed percentages were weighted for the probability of selection.

18–49 years

0 20 40 60 80 100

50–59 years

0 20 40 60 80 100

60–64 years

0 20 40 60 80 100

65–74 years

0 

Percent Percent Percent Percent 
14

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

4

0 20 40 60 80 100

50–59 years

4

0 20 40 60 80 100

60–64 years

4

0 20 40 60 80 100

65–74 years

4

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
86

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

96

0 20 40 60 80 100

50–59 years

96

0 20 40 60 80 100

60–64 years

96

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
44

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

38

0 20 40 60 80 100

50–59 years

33

0 20 40 60 80 100

60–64 years

27

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
42

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

58

0 20 40 60 80 100

50–59 years

63

0 20 40 60 80 100

60–64 years

69

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
53

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

44

0 20 40 60 80 100

50–59 years

49

0 20 40 60 80 100

60–64 years

62

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
53

32

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

44

43

0 20 40 60 80 100

50–59 years

44

49

0 20 40 60 80 100

60–64 years

47

62

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
53

32

25

0 20 40 60 80 100

No medical condition

≥1 medical condition

1-2 conditions

>=3 conditions

Obesity

Cardovascular disease...

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease...

Chronic metabolic disease,...

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory...

Frequency of underlying medical conditions among non-pregnant adulassociated hospitalizations by age group — RSV-NET, 2014–2015 to 2012022–2023

18–49 years

44

43

37

0 20 40 60 80 100

50–59 years

44

49

41

0 20 40 60 80 100

60–64 years

47

62

42

0 20 40 60 80 100

65–74 years

0 

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

Percent Percent Percent Percent 
Prevalence of certain medical conditions

* among non-pregnant adults 

associated hospitalizations (RSV-NET, 2014–2015 to 2017–2018 and 202among the general population (National Center for Health Statistics

†, 2

group

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of pathospitalizations during the 2022–2023 season. Displayed percentages were weighted for the probability of selection.†National Center for Health Statistics. United States, 2022. National Health Interview Survey. Generated interactively: Oct 17, 2023 from https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/in

50–64 years ≥65 ye

General

population RSV-NET RSV- NET/ 

Pop

General 

population 

Condition % (95% CI) % (95% CI) % (95% CI) % 

Coronary artery disease 5.0 (4.4, 5.6) 18.9 (16.9, 21.0) 3.8 15.3 (14.4, 16.2) 31.COPD 6.2 (5.5, 6.9) 35.4 (32.9, 37.9) 5.7 9.8 (9.1, 10.5) 33.Diabetes mellitus 13.8 (12.9, 14.7) 37.7 (35.1, 40.4) 2.7 20.1 (19.1, 21.1) 31.Asthma 9.1 (8.4, 9.9) 28.6 (26.3, 31.0) 3.1 8.0 (7.3, 8.6) 17.Obesity 37.6 (36.2, 38.9) 46.4 (43.7, 49.0) 1.2 30.4 (29.2, 31.6) 28.
Frequency of underlying medical conditions among adults aged 50–59 admissions and RSV-associated hospitalizations — RSV-NET, 2014–2015 2022–2023

ICU admissions Hospitalizations

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

0 20 40 60 80 100

No medical condition

≥1 medical condition

Cardovascular disease (overall)

Obesity

Diabetes

COPD

Heart failure

Immune compromised

Chonic kidney disease

Asthma

Coronary artery disease (includes CABG, MI)

Other chronic lung disease

Neurologic condition

Chronic liver disease

Chronic metabolic disease, not including diabetes

Blood disorders

Autoimmune/inflammatory disease

0 20 

No medical condition

≥1 medical condition

Obesity

Cardovascular disease (overall)

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease (includes CABG, MI)

Chronic metabolic disease, not including diabetes

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory disease

Percent 
Frequency of underlying medical conditions among adults aged 50–59 admissions and RSV-associated hospitalizations — RSV-NET, 2014–2015 2022–2023

ICU admissions Hospitalizations

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

4

95

49

44

40

35

30

29

26

25

19

17

16

14

11

4

2

0 20 40 60 80 100

No medical condition

≥1 medical condition

Cardovascular disease (overall)

Obesity

Diabetes

COPD

Heart failure

Immune compromised

Chonic kidney disease

Asthma

Coronary artery disease (includes CABG, MI)

Other chronic lung disease

Neurologic condition

Chronic liver disease

Chronic metabolic disease, not including diabetes

Blood disorders

Autoimmune/inflammatory disease

4

3

29

26

23

21

17

17

15

12

10

5

4

0 20 

No medical condition

≥1 medical condition

Obesity

Cardovascular disease (overall)

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease (includes CABG, MI)

Chronic metabolic disease, not including diabetes

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory disease

Percent 
Frequency of underlying medical conditions among adults aged 50–59 admissions and RSV-associated hospitalizations — RSV-NET, 2014–2015 2022–2023

ICU admissions Hospitalizations

*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during the 2014–2015 to 2017–2018 seasons, and for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations percentages were weighted for the probability of selection.

4

95

49

44

40

35

30

29

26

25

19

17

16

14

11

4

2

0 20 40 60 80 100

No medical condition

≥1 medical condition

Cardovascular disease (overall)

Obesity

Diabetes

COPD

Heart failure

Immune compromised

Chonic kidney disease

Asthma

Coronary artery disease (includes CABG, MI)

Other chronic lung disease

Neurologic condition

Chronic liver disease

Chronic metabolic disease, not including diabetes

Blood disorders

Autoimmune/inflammatory disease

4

3

29

26

23

21

17

17

15

12

10

5

4

0 20 

No medical condition

≥1 medical condition

Obesity

Cardovascular disease (overall)

Diabetes

COPD

Asthma

Immune compromised

Heart failure

Chonic kidney disease

Neurologic condition

Coronary artery disease (includes CABG, MI)

Chronic metabolic disease, not including diabetes

Other chronic lung disease

Chronic liver disease

Blood disorders

Autoimmune/inflammatory disease

Percent 
Percentages of non-pregnant adults ≥18 years with RSV-assohospitalization who experienced severe outcomes by age gro2022–2023

16%

21%

16%

21%

4%

10%

4%

6%

2%

3%

2%

4%

0%5%

10%15%20%25%

18–49 50–59 60–64 65–74 

Proportion of Hospitalized Adults with Severe 

Outcome

ICU Mechanical ventilation Died

ICU = intensive care unit*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizations durin

Displayed percentages were weighted for the probability of selection.
16

21

16

21

17

18

18

17

16

21

20

19

05

10152025

18–49 50–59 60–64 65–74 

Proportion of Hospitalizations Admitted to ICU

RSV Influenza COVID

Percentages of non-pregnant adults ≥18 years with laboratorhospitalization admitted to intensive care unit (ICU), RSV-NECOVID-NET, 2022–2023

*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV, Influenza, and COVID-19 hospitalizations during the were weighted for the probability of selection.†Patients with severe disease may be more likely to be tested for RSV, Influenza, or COVID-19 which may overestimate proportions of patients admitted to the ICU.

‡Data shown here does not take patient vaccination or treatment status into account.§FluSurv-NET surveillance occurred during October 2022–April 2023; RSV-NET and COVID-NET surveillance occurred year-round.
2

3

2

4

1

3

3

3

1

3

4

6

01234567

18–49 50–59 60–64 65–74 

Proportion of Hospitalizatizations with In-hospital

Death

RSV Influenza COVID

Percentages of non-pregnant adults ≥18 years with laboratorhospitalization with in-hospital death

*, RSV-NET, FluSurv-NET

2022–2023

*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV, Influenza, and COVID-19 hospitalizations during the were weighted for the probability of selection.†Patients with severe disease may be more likely to be tested for RSV, Influenza, or COVID-19 which may overestimate proportions of patients admitted to the ICU.

‡Data shown here does not take patient vaccination or treatment status into account.§FluSurv-NET surveillance occurred during October 2022–April 2023; RSV-NET and COVID-NET surveillance occurred year-round.
Distribution of RSV-associated hospitalizations and severe ouamong adults ≥18 years by age group, RSV-NET, 2022–2023

17% 15% 13%

8%

12% 14% 22%

9%

9% 9%

7%

4%

23%

28%

26%

22%

39%

33% 31%

58%

0%

10%20%30%40%50%60%70%80%90%

100%

Hospitalizations ICU Mechanical ventilation Death

Proportion

18–49 50–59 60–64 65–74 ≥75 

ICU = intensive care unit*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizaseason. Displayed percentages were weighted for the probability of selection.
Distribution of RSV-associated hospitalizations and severe ouamong adults ≥18 years by age group, RSV-NET, 2022–2023

17% 15% 13%

8%

12% 14% 22%

9%

9% 9%

7%

4%

23%

28%

26%

22%

39%

33% 31%

58%

0%

10%20%30%40%50%60%70%80%90%

100%

Hospitalizations ICU Mechanical ventilation Death

Proportion

18–49 50–59 60–64 65–74 ≥75 

ICU = intensive care unit*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizaseason. Displayed percentages were weighted for the probability of selection.
Distribution of RSV-associated hospitalizations and severe ouamong adults ≥18 years by age group, RSV-NET, 2022–2023

17% 15% 13%

8%

12% 14% 22%

9%

9% 9%

7%

4%

23%

28%

26%

22%

39%

33% 31%

58%

0%

10%20%30%40%50%60%70%80%90%

100%

Hospitalizations ICU Mechanical ventilation Death

Proportion

18–49 50–59 60–64 65–74 ≥75 

ICU = intensive care unit*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizaseason. Displayed percentages were weighted for the probability of selection.
Distribution of RSV-associated hospitalizations and severe ouamong adults ≥18 years by age group, RSV-NET, 2022–2023

17% 15% 13%

8%

12% 14% 22%

9%

9% 9%

7%

4%

23%

28%

26%

22%

39%

33% 31%

58%

0%

10%20%30%40%50%60%70%80%90%

100%

Hospitalizations ICU Mechanical ventilation Death

Proportion

18–49 50–59 60–64 65–74 ≥75 

ICU = intensive care unit*Clinical data, including severe outcomes, were collected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospitalizaseason. Displayed percentages were weighted for the probability of selection.
Median age of non-pregnant adults ≥18 years with RSV-assochospitalizations by race and ethnicity* — RSV-NET, 2014–2012023

Unweighted Weighted

% Median Age In

r

Overall 17,847 - 69 

White 10,755 62.2 73 Black 3,529 20.4 62 Hispanic 1,434 8.3 62 Asian or Pacific Islander 1,020 5.9 73 American Indian or Alaska Native 90 0.5 64 Multirace 89 0.5 75 Unknown 367 2.1 68 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
Median age of non-pregnant adults ≥18 years with RSV-assochospitalizations by race and ethnicity* — RSV-NET, 2014–2012023

Unweighted Weighted

% Median Age In

r

Overall 17,847 - 69 

White 10,755 62.2 73 Black 3,529 20.4 62 Hispanic 1,434 8.3 62 Asian or Pacific Islander 1,020 5.9 73 American Indian or Alaska Native 90 0.5 64 Multirace 89 0.5 75 Unknown 367 2.1 68 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
Distribution of RSV-associated hospitalizations among adults race and ethnicity

* and age group— RSV-NET, 2014–2015 to 2

39%

53%

62%

69%

29%

23%

21%

17%

18%

13%

8% 6% 

8% 6% 5% 5% 

0%

10%20%30%40%50%60%70%80%90%

100%

18–49 50–59 60–64 65–74 

Proportion

White Black Hispanic Asian or Pacific Islander

*Black, White, and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be of any race. American Indian/Al

due to small numbers.
Distribution of RSV-associated ICU admissions among adults race and ethnicity* and age group — RSV-NET, 2014–2015 to 

41%

60% 58%

69% 

39%

22% 30%

19% 

11% 8%

8% 6%

9% 9% 5% 5% 

0%

10%20%30%40%50%60%70%80%90%

100%

18–49 50–59 60–64 65–74 

Proportion

White Black Hispanic Asian or Pacific Islander

*Black, White, and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be of any race. American Indian/Al

due to small numbers.
Burden-adjusted hospitalization rate ratios among adults ≥18 and ethnicity* — RSV-NET, 2016–2017 to 2019–2020

Maximum rate ratAverage rate ratio Minimum rate rati

01234

18–49 50–59 60–64 65–74 

White

Maximum rate ratio Average rate ratio (2Minimum rate ratio 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
01234

18–49 50–59 60–64 65–74 

White Hispanic

Burden-adjusted hospitalization rate ratios among adults ≥18 and ethnicity* — RSV-NET, 2016–2017 to 2019–2020

Maximum rate ratio Average rate ratio (2Minimum rate ratio 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
01234

18–49 50–59 60–64 65–74 

Asian or Pacific Islander White Hispa

Burden-adjusted hospitalization rate ratios among adults ≥18 and ethnicity* — RSV-NET, 2016–2017 to 2019–2020

Maximum rate ratio Average rate ratio (2Minimum rate ratio 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
Maximum rate ratAverage rate ratio Minimum rate rati

01234

18–49 50–59 60–64 65–74 

Asian or Pacific Islander White Hispanic 

Burden-adjusted hospitalization rate ratios among adults ≥18 and ethnicity* — RSV-NET, 2016–2017 to 2019–2020

Maximum rate ratio Average rate ratio (2Minimum rate ratio 

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
01234

18–49 50–59 60–64 65–74 

Asian or Pacific Islander White Hispanic Black American I

Maximum rate ratio Average rate ratio (2Minimum rate ratio 

Burden-adjusted hospitalization rate ratios among adults ≥18 and ethnicity* — RSV-NET, 2016–2017 to 2019–2020

*Black, White, American Indian/Alaska Native and Asian/Pacific Islander people were categorized as non-Hispanic; Hispanic people could be o
Coronavirus and Other Respiratory Viruses DivisionAmadea BrittonFiona HaversMichael MelgarKadam PatelHuong PhamChris TaylorMichael Whitaker

Influenza Division

Alissa O’HalloranCatherine BozioDawud UjamaaRESP-NET Site Investigators an

Acknowledgements
For more information, contact CDC

1-800-CDC-INFO (232-4636)TTY: 1-888-232-6348 www.cdc.govThe findings and conclusions in this report are those of the authors and do not necessarily represent the official 

position of the Centers for Disease Control and Prevention.Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.